Aldeyra Therapeutics rises as eye treatment meets late-stage study goals

Aldeyra Therapeutics

15/06/2023 12:23

** Shares of drug developer Aldeyra Therapeutics Inc
 ALDX.O  rise 11.7% to $11.70 before the bell
    ** Co says its experimental drug, reproxalap, to treat an
inflammatory eye disease met the main goal of reducing itching
in a late-stage study
    ** The drug also helped reduce redness and tearing caused
due to the disease when compared to placebo- co
    ** As of last close, stock had gained 50.22% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))